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The introduction of imatinib in the treatment of chronic myeloid leukaemia (CML) 
represents the most successful example of targeted therapy in human cancer. 
However, leukaemic stem cells (LSCs) are insensitive to tyrosine kinase inhibitors 
(TKIs) and contribute to disease persistence by representing a reservoir of self-
renewing cells that replenish the disease upon drug discontinuation. This has re-
focused the interest of scientists towards drug combinations i.e. treating with TKIs 
and simultaneously targeting alternative survival mechanisms. One candidate target 
mechanism is autophagy, a cellular recycling process that acts as a cytoprotective 
shield in CML cells in response to TKI-induced stress and in other cancer cells 
surviving in an inhospitable microenvironment. On that basis, inhibition of autophagy 
has now become an exciting option for combination treatment in cancer and clinical 
trials have been initiated in solid and haemopoietic tumours such as CML, chronic 
lymphocytic leukaemia (CLL) and multiple myeloma. This review describes the 
biology of CML and elucidates how the molecular driver BCR-ABL led to the 
development of TKIs. We then discuss the molecular regulation of autophagy and the 
potential for autophagy inhibition as the next step in our attempt to tackle the problem 




Fifty years ago a genetic link to cancer was provided by Peter C. Nowell and David 
Hungerford, who for the first time described an unusual small chromosome present in 
leukocytes from patients with chronic myeloid leukaemia (CML). This abnormality, 
designated as the Philadelphia (Ph) chromosome after the city in which it was 
discovered, was found in all malignant cells of CML patients and is now considered 
the hallmark of CML.1 In 1973 Janet Rowley demonstrated that the Ph chromosome 
resulted from a reciprocal translocation between the long arms of chromosomes 9 and 
22, t(9:22)(q34;q11).2 Later, it was shown that this alteration generates a fusion 
between c-ABL (human homologue of the Abelson Murine Leukaemia virus), a 
tyrosine kinase encoding oncogene, and BCR (Breakpoint Cluster Region), the 
function of which is still not clear.3 The chimeric BCR-ABL protein possesses 
cellular transforming ability which is ascribed to the elevated tyrosine kinase (TK) 
activity of the molecule compared to the native c-ABL.4-5 Further studies have 
established BCR-ABL as a leukaemogenic oncogene and both mouse models and in 
vitro assays have shown that BCR-ABL, as the sole oncogenic event, is sufficient to 
induce leukaemia.6 
 
Molecular mechanisms of BCR-ABL 
 
There are three major forms of the BCR-ABL oncoprotein, depending on the break 
point occurring within the BCR gene. The most common is the p210 kDa protein 
(e13a2 or e14a2 transcript) that is found in the majority of CML cases and in 
approximately one third of adults with Ph-positive acute lymphoblastic leukaemia 
(ALL).7 A p190 kDa protein (e1a2 transcript) is expressed in the remaining Ph-
positive ALL patients and rarely in patients with CML. The third fusion protein (p230 
kDa; e19a2 transcript) has been identified in the rare neutrophilic  CML (CML-N).8 
All three major BCR-ABL fusion proteins induce a similar CML-like syndrome in 
mice, but differ in their ability to induce lymphoid leukaemia.9  
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Key BCR-ABL-activated signaling pathways  
Once established as the oncogene causing CML, significant effort was invested in 
understanding the molecular mechanism of action of BCR-ABL. To date several 
signaling pathways affected by the constitutively active BCR-ABL have been 
identified, as well as numerous binding partners and substrates that provide a link 
between these pathways and the defects that characterise CML (Figure 1). 
BCR-ABL mimics growth factor stimulation in many ways; activation of these 
signaling pathways leads to (i) increased proliferation and decreased apoptosis of 
haemopoietic stem and progenitor cells, giving rise to a massive increase in myeloid 
cell numbers, (ii) reduced growth factor-dependence, and (iii) abnormal interaction 
with the extra-cellular matrix and stroma, leading to premature release of immature 
myeloid cell into the circulation. These events, together with the fact that BCR-ABL 
promotes genomic instability, ultimately drive disease progression.7 
 
RAS/MAP kinase pathway: The RAS pathway is well studied, both in normal and 
cancer cells, and activating mutations in RAS are found in many human cancers. 
Phosphorylation of tyrosine 177 within the BCR region of BCR-ABL allows 
interaction with the adapter molecule GRB2, an important factor in human 
haemopoietic progenitor transformation.10 Even though BCR-ABL does not affect the 
level of GRB2 expression, this binding enables the formation of complexes between 
GRB2 and SOS (son of sevenless; a guanine-nucleotide exchange factor of RAS), 
leading to activation of RAS signaling.11  
 
PI3-K/AKT pathway: Another pathway commonly activated in various cancers and a 
crucial event in tumourigenesis is the PI3-K/AKT pathway. 12 Activation of receptor 
TKs (RTKs) by growth factors or BCR-ABL expression induces activation of this 
pathway.13 Many molecules downstream of AKT have been shown to be important 
players in mediating the leukaemogenic effects of BCR-ABL, either through 
activation or in-activation, including BAD, MDM2, mammalian target of rapamycin 
(mTOR) and the FOXO sub-class of forkhead factors (FOXO1, FOXO3a and 
FOXO4);12 (i) BAD mediates its pro-apoptotic effect by binding to anti-apoptotic 
BCL-2 proteins and preventing their functions;14 (ii) MDM2 is a negative regulator of 
p53 and has been shown to be upregulated by BCR-ABL;15 (iii) mTOR functions 
mainly in the translational control of proteins involved in cellular growth, size and 
cycle regulation.16 In BCR-ABL expressing cells, mTOR is active and rapamycin, an 
inhibitor of mTOR, suppresses the growth of BCR-ABL transformed cells.17 mTOR 
also negatively regulates autophagy (discussed later in this review). Finally, (iv) the 
FOXO transcription factors are involved in cell cycle arrest and/or apoptosis.18 BCR-
ABL transformation has been shown to inhibit FOXO3a activity by maintaining its 
constitutive phosphorylation and cytoplasmic retention.19  
 
JAK-STAT pathway: Another anti-apoptotic pathway activated by BCR-ABL is the 
JAK-STAT pathway. Recent in vivo experiments in mouse models have portrayed 
Stat5 as an indispensible factor for induction and maintenance of Bcr-Abl positive 
leukaemia, underlining the critical role of STAT5 in CML.20-21 Furthermore, a recent 
study by Warsch and colleagues explored the role of STAT5 in the development of 
TK inhibitor (TKI)-resistance, demonstrating that enhanced STAT5 levels reduced 
sensitivity to TKIs in a STAT5-dependent, but JAK2-independent manner.22 The role 
of the RAS and the JAK-STAT pathways in the cellular response to various growth 
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factors could explain why many growth factor dependent cell lines become 
independent following BCR-ABL expression.6 Evidence has emerged illustrating an 
autocrine loop dependent on BCR-ABL-induced secretion of growth factors. BCR-
ABL induces an interleukin-3 (IL-3) and granulocyte-colony-stimulating factor (G-
CSF) positive feedback mechanism in early progenitor cells which could alter critical 
cell cycle regulators.23 Autocrine production of IL-3 and G-CSF may therefore play a 
role in promoting cell cycle entry of primitive leukaemic stem cells (LSC) and early 
progenitors during the chronic phase (CP) of disease, where the G-CSF receptor is 
expressed.24  
 
CML treatment  
 
Disease course and progression: The natural history of CML is triphasic, involving 
an initial chronic phase (CP), lasting 3-5 years, followed by progression either to 
accelerated phase (AP) and then blast crisis (BC) or directly to BC. These advanced 
phases of the disease carry a much poorer prognosis with median survival measured 
in months. CML progression is generally a gradual and complex process promoted by 
the accumulation of secondary genetic and epigenetic changes, rather than isolated 
alterations. As reviewed in Perrotti et al, BCR-ABL expression and activity may be 
significantly elevated at advanced stage via gene amplification, increased promoter 
activity or other less direct mechanisms, such as decreased miR-203 levels, inhibition 
of SHP-1 phosphatase and inactivation of PP2A.25 BCR-ABL-driven manipulation of 
the transcriptome plays a key role in disease progression by activating mitogenic, 
anti-apoptotic and anti-differentiation mediators (e.g. MYC, JAK2, hnRNP-E2, 
MDM2, STAT5, BMI-1 and BCL-2), inhibiting tumour suppressors (e.g. p53 or 
CEBPa), or through aberrant splicing of modulators like GSK3β and PYK2.25  
 
TKIs in the management of CML: Over the 1980s increased understanding of the 
mechanism of BCR-ABL as the main driver of the disease led to the development of 
an Abl specific TKI, imatinib (Gleevec, Glivec).26 Preclinical studies followed by 
clinical trials verified the success of imatinib in specifically targeting BCR-ABL-
positive cells and subsequently imatinib has been established as the standard therapy 
for CML.  
 
The problem of resistance: The mechanisms of imatinib-resistance have been 
extensively investigated and it is now known that approximately 50% of patients who 
relapse on imatinib have BCR-ABL point mutations in more than 40 different amino 
acids within the ABL kinase domain.27 These findings led to the rapid development of 
second generation TKIs to circumvent this problem. Nilotinib and dasatinib both 
demonstrate increased potency over imatinib and inhibit most imatinib resistance 
mutants, except T315I.28,29 Both inhibitors have now been approved by FDA and 
EMEA and are used routinely and very effectively as second-line therapy for patients 
with resistance or intolerance to imatinib.30-31 Interestingly, as reported by Saglio et al 
and Kantarjian et al, administration of nilotinib or dasatinib to newly diagnosed CML 
CP patients resulted in higher frequencies and faster achievement of cytogenetic and 
molecular responses compared to standard dose imatinib (400mg daily). By 12 
months of treatment there was a trend towards reduced progression rates which 
achieved significance for nilotinib.32-33 Based on these remarkable results, both drugs 
are now undergoing approval for first-line use in many countries. For the T315I 
mutant inhibitors including ponatinib (AP24534), a pan BCR-ABL inhibitor (Phase 
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II) and DCC-2036, a “switch-control” inhibitor (Phase I), have advanced to clinical 
trials.34-37  
 
Combination studies: In an effort to make patients’ responses more robust, clinical 
trials have been launched involving the use of TKIs in combination with other drugs 
that could potentially augment TKI-induced cell death. One such study combines 
imatinib with peginterferon alfa-2a or cytarabine and currently shows a significant 
advantage for the interferon combination in terms of molecular responses (overall 
survival and progression free survival unchanged).38 Further smaller trials are being 
conducted that combine imatinib with zileuton (Phase I), panabinostat, sodium 
valproate (Phase I), arsenic trioxide (Phase II) or hydroxychloroquine (Phase II) and 
there is a Phase I evaluation of dasatinib with a SMO inhibitor underway.39  
 
The problem of persistence: Disease persistence refers to the presence of primitive 
BCR-ABL-positive CD34+ cells that are inherently insensitive to TKIs in patients 
who are otherwise responding well. Whilst the majority of these patients are in major 
molecular response with BCR-ABL transcripts detectable by Q-RT-PCR, recent data 
also confirm the presence of BCR-ABL expressing cells by genomic PCR in patients 
in complete molecular remission on TKIs.40-41 We and others have shown that four of 
the currently available TKIs (imatinib, nilotinib, dasatinib and bosutinib) have strong 
anti-proliferative effects, but fail to induce cell death in primitive stem/progenitor 
cells. This may explain why primitive leukaemic cells are present in the bone marrow 
of patients with established complete cytogenetic response (CCR) over 5 years on 
imatinib.42-46 It is also in keeping with the rapid recurrence of the ability to detect 
BCR-ABL transcripts in most patients with apparent complete molecular remission 
following imatinib discontinuation.40,47 In recent studies by the French and Australian 
groups disease recurrence rates were 61% (of 100 patients) and 56% (of 18 patients), 
respectively, in selected patients who had undetectable disease maintained over more 
than 2 years prior to TKI discontinuation. These clinical observations have prompted 
the development of stem cell directed therapy and have raised the debate as to 
whether CML stem cells are oncogene addicted, i.e. if CML stem cells are dependent 
on BCR-ABL for survival. Recent results from Corbin et al and our laboratory 
(unpublished) suggest that CML stem cells can survive following complete BCR-
ABL inhibition and are therefore not oncogene addicted.48 
Given that BCR-ABL expressing stem cells can survive without BCR-ABL signaling, 
combination therapy is likely to be one way to circumvent the problem of disease 
persistence. However, improving existing or combining different BCR-ABL 
inhibitors is unlikely to tackle the problem of persisting CML stem cells that are able 
to survive despite full BCR-ABL inhibition.48 Therefore, alternative survival 
pathways responsible for leukaemic stem cell survival following oncogene 
inactivation must be examined in order to apply successful stem cell directed therapy, 
potentially leading to patient cure. One example of such a survival pathway is 
macroautophagy (autophagy).49-50 
 
Molecular mechanism of autophagy  
 
Autophagy [self (auto)-eating (phagy)] is a recycling process that leads to 
sequestration and degradation of damaged  proteins and other intracellular material 
within lysosomes (Figure 2).51 Recycling of these intracellular constituents can serve 
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as an alternative source of energy during periods of metabolic stress or starvation to 
maintain cellular homeostasis and survival.52 
An understanding of the molecular regulation of autophagy has been gained only in 
the past 10 years. Autophagy has been thoroughly examined in yeast where many 
autophagy-related genes (ATG) have been identified and several of these genes have 
now been shown to have mammalian orthologues. The process can be divided into 
sequential steps that ultimately result in breakdown of cytoplasmic material within the 
lysosomes (Figure 2).  
 
Initiation: It has recently been elucidated that the initiation of autophagy starts with 
activation of a serine/threonine kinase complex containing ULK1 and 2 (yeast Atg1), 
ATG13, and FIP200.53 During glucose starvation, AMP activated protein kinase 
(AMPK) phosphorylates ULK1, promoting activation of autophagy. Alternatively, 
when nutrient sufficiency is established mTOR blocks this interaction.54-55 Hence, 
mTOR acts as the main regulator of autophagy by directly inhibiting the 
ULK1/2/ATG13/FIP200 complex and other ATG proteins.56 Consequently, upon 
mTOR inhibition (i.e. cell starvation or rapamycin treatment), the UKL1 complex 
dissociates from mTOR allowing it to accumulate at an isolation cup-shaped 
membrane, called the phagophore.53  
 
Autophagosome formation: The class III PI3-K (PI3-K-III) VPS34 is critical for 
further expansion of phagophores to autophagosomes, double-membraned vesicles 
which are the main mediators of autophagy.57 VPS34 forms a complex with VPS15 
and autophagy protein BECLIN1 (yeast Atg6).51 The anti-apoptotic protein BCL-2 
can interact with the BH3 domain of BECLIN1 and inhibit autophagy.58 This 
interaction is reduced upon starvation, freeing BECLIN1 to activate autophagy.59 It 
has been suggested that this anti-autophagy function of BCL-2 might maintain 
autophagy at levels that are optimal for cell survival. BCL-2 has also been shown to 
suppress autophagy by inhibiting cytosolic calcium elevation, which has been shown 
to induce autophagy.60 UVRAG (UV irradiation resistance-associated gene) and 
AMBRA1 are other proteins that have been shown to interact with BECLIN1 and 
positively regulate autophagy, indicating that BECLIN1-dependent autophagy might 
be tightly regulated by BECLIN1 binding partners.61 
Autophagosome completion is mediated by two ubiquitin-like conjugation systems: 
the ATG12/ATG5 and ATG8-PE [(ATG8 is also known as microtubule-associated 
protein 1 light chain 3; LC3), (PE; phosphatidylethanolamine)] conjugation systems, 
which are both essential for autophagy.62 The ATG8-PE process is mediated by 
ATG4, ATG7 (E1-ubiquitin enzyme) and ATG3 (E2-ubiquitin enzyme) that perform 
the lipid modification of ATG8. ATG4 also cleaves the amide bond between ATG8 
and PE to release the protein from membranes.63 The ATG12/ATG5 process starts 
with conjugation of ATG12 to ATG5 with ATG10 acting as an E2 enzyme. The 
ATG12/ATG5 conjugate then interacts with ATG16 and this complex 
(ATG12/ATG5/ATG16) exerts an E3 enzyme-like function and regulates the ATG8-
PE binding to the autophagosomal membrane.64 LC3 (ATG8) has been investigated 
most thoroughly and acts now as the main marker for autophagosomes. LC3 
maturation completes with the reversible conjugation of LC3-I to PE (by ATG7 and 
ATG3) to form LC3-II on the surface of autophagosomes.65 This alteration is used to 
monitor autophagy by various assays. However, correct interpretation of LC3-I/II 
conversion is very important as accumulation of autophagosomes could, for example, 
reflect either increased autophagosome formation due to an increase in autophagic 
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activity, or inhibition of autophagosome turnover. Leading scientists in the field have 
published detailed guidelines and a standard set of criteria for monitoring autophagy 
that should help new investigators that join this growing field.66 
 
Maturation and degradation: The maturation process includes the fusion of the outer 
membrane of autophagosomes with lysosomes to form autolysosomes. The 
mechanism of this process is not very well understood but it has been shown that 
LAMP1/2 (lysosomal proteins), RAB7 (small GTPase) and cathepsinD/B/L are all 
involved in the autophagosome maturation, with RAB7 and LAMP1/2 potentially 
facilitating autophagosome and lysosome fusion.67 UVRAG has also been shown to 
be involved in the maturation step, where it stimulates RAB7 GTPase activity and 
autophagosome fusion with lysosomes.57 At the final autolysosomes, the inner single 
membrane of the autophagosomes and its cargo is lysed by lysosomal hydrolases, 
especially cathepsins and the content degraded.68 
However, autophagy should not be viewed only as recycling machinery. This process 
is constantly taking place at basal levels in the majority of mammalian cells, as early 
as the stage of oocyte fertilisation, and is involved in a plethora of mechanisms and 
pathways including cell development, differentiation, homeostasis, quality control, 
aging, infection and immunity, neurodegeneration and cancer.69 
 
The paradoxical role of autophagy in cancer 
 
Autophagy has been suggested to work as a double-edged sword in cancer 
development and progression, by inducing both tumour cell survival and death. These 
diverse effects depend to a large degree on the type of tumour, stage of disease and 
nature of treatment.70 Basal autophagy within normal cells is pivotal since it (i) 
promotes genetic stability by removing damaged mitochondria that would otherwise 
produce ROS (reactive oxygen species) and damage the DNA, and (ii) functions as a 
“guardian” of the proteome and promotes adaption under changing conditions and/or 
stress.69 The first strong link between autophagy and cancer was published in 1999 by 
Levine’s laboratory showing that BECLIN1 is a haploinsufficient tumour 
suppressor.71 Subsequent studies revealed that BECLIN1 is lost at high frequency in 
human breast, ovarian and prostate cancers and BECLIN1-heterozygous mice are 
prone to tumour development.72 On the other hand, autophagy inhibition leads to 
enhanced apoptotic effect of irradiation, alkylating agents and arsenic trioxide in 
tumour cells.70 Hence, autophagic activity may suppress tumourigenesis in healthy 
cells by removing damaged organelles and proteins, reducing ROS and suppressing 
necrosis-induced inflammation that can lead to cancer development when chronic.73 
However, it seems to have a cytoprotective role in established tumour cells and thus, 
its inhibition could enhance apoptosis. Greater understanding of the functional role of 
autophagy with regard to cancer in the future will be critical in order to enable 
specific autophagy inhibition/promotion in a range of tumours for therapeutic gain. 
 
Pharmacological inhibition of autophagy 
 
Several inhibitors that disrupt the autophagy process are available and frequently used 
to study the role of autophagy in tumourigenesis and in response to cancer therapy. 3-
methyladenine (3-MA) is a PI3-K-III inhibitor and therefore inhibits autophagosome 
formation. Wortmannin (pan PI3-K inhibitor) has also been used to inhibit autophagy 
at its early stage. In contrast to the PI3-K-III inhibitors, bafilomycin A1, chloroquine 
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(CQ), hydroxychloroquine (HCQ) and NH4Cl inhibit autophagy at a later stage by 
preventing the fusion of autophagosomes and lysosomes.74  Bafilomycin A1 is a 
specific inhibitor of vacuolar-type H+-ATPase, whereas CQ, HCQ and NH4Cl are 
lysosomotropic drugs that raise intracellular pH and therefore impair autophagosome 
and lysosome fusion and autophagic protein degradation. Although these drugs are 
not specific autophagy inhibitors and will have an effect on other pathways, they have 
proven very useful in studying and inhibiting autophagy in the laboratory. Autophagy 
inhibition in a specific manner is currently performed in vitro via siRNA-mediated 
knockdown of essential autophagy genes, such as BECLIN1, ATG5 and ATG7. The 
challenge for the future is the development of autophagy specific drugs. With our ever 
increasing understanding of the main regulators of this key process this should not be 
far away. There are already some critical players that appeal as attractive drug targets, 
such as the kinases in the ULK1 protein complex, VPS34 and essential ATG 
autophagy proteins (e.g. ATG4 or ATG7), for which activity could be repressed with 
small inhibitory compounds.70 
 
Autophagy in CML 
 
BCR-ABL signaling, like growth factor activation, leads to activation of the PI3-
K/AKT pathway and mTOR. In line with this, it has been demonstrated that BCR-
ABL expressing mouse haemopoietic precursor cells have low basal levels of 
autophagy, but are highly dependent on this process.75 Inhibition of BCR-ABL by 
TKIs has now been shown to not only induce apoptosis but also autophagy, a similar 
effect to that seen following growth factor withdrawal.49 But the questions of (i) what 
level of autophagy is taking place within haemopoietic stem cells (HSCs) and (ii) 
what is its role remain unclear. However, two recent studies have elucidated the field. 
Firstly, Liu et al reported that FIP200 is indispensible for the function and 
maintenance of fetal murine HSCs in a cell-autonomous manner.76 The hypothesis 
that autophagy is essential for the maintenance of HSCs was further supported by 
Mortensen et al who showed in mice that adult Atg7-deficient HSCs fail to engraft 
lethally irradiated recipients, clearly depicting autophagy as an essential modulator of 
HSCs maintenance.77 
Many recent publications have shown that chemotherapeutic agents used in the 
treatment of haemopoietic malignancies, including CML, induce both apoptosis and 
autophagy. The ultimate fate of a cell resembles a hub that integrates all the signals 
from the apoptosis, autophagy, necrosis and senescence responses. Hence, the choice 
between death and survival depends critically on the balance between these 
mechanisms. However, the ultimate decision between apoptosis and survival may also 
differ dependent on the maturational status of the cell. As hypothesised in a recent 
review by Calabretta and Salomoni, TKI treatment in CML could potentially trigger 
different signaling pathways in primitive CD34+CD38- cells versus their progenitors, 
i.e. inhibition of BCR-ABL could trigger apoptosis within the progenitors but 
protective autophagy at the primitive stem cell level.78  
In many situations targeting autophagy has increased the effect of the anticancer drug, 
although it is not yet clear whether autophagy inhibition is enhancing programmed or 
necrotic cell death. Nonetheless, by using mouse models it has been convincingly 
shown that autophagy serves as a survival pathway and its inhibition enhances p53 or 
drug-induced cell death in lymphoma cells.79 This indicates that autophagy inhibitors, 
such as CQ, in combination with therapies designed to induce cell death, could be 
beneficial in the treatment of haematological neoplasms. Recently a number of 
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publications have linked CML with autophagy (Table 1). In 2006 it was shown that 
the neurotoxin crotoxin induced autophagy in K562 cells and blockade of autophagy 
with 3-MA and NH4Cl potentiated the neurotoxin’s cytotoxicity.80 One year later 
Carew et al showed that targeting autophagy using CQ enhanced the anticancer 
activity of the histone deacetylase inhibitor SAHA in imatinib-resistant primary CML 
cells.81 These reports represented the first evidence that CML cells induce autophagy 
as a cell survival response following treatment with anticancer drugs, suggesting 
autophagy inhibition as a novel strategy with therapeutic implications for imatinib 
resistance.82 The first evidence that inhibition of BCR-ABL activity induced 
autophagy came one year later when bafetinib (INNO-406), a potent c-ABL and LYN 
kinase inhibitor, was shown to induce autophagy in K562 cells.83 Again, this 
autophagy response had a protective role as treatment with CQ enhanced cell death 
induced by bafetinib. A few months later, imatinib was also shown to induce 
autophagy in K562 cells and co-treatment with imatinib and CQ markedly enhanced 
imatinib-induced death.84 
The strongest evidence that autophagy inhibition might enhance the therapeutic 
effects of imatinib in the treatment of CML was shown in 2009.49-50 There we 
demonstrated that autophagy inhibition combined with TKIs (imatinib, dasatinib or 
nilotinib) resulted in near complete elimination of phenotypically and functionally 
defined CML stem cells. Our data were further supported by a study from Crowley et 
al who also showed that autophagy works as a cellular protection against imatinib-
induced stress.85 Despite a recently published role for ABL kinases in the regulation 
of late-stage autophagy, the effect in our study was specific to BCR-ABL inhibition.86 
Autophagy was not induced upon imatinib treatment in a cell line carrying the T315I 
mutation and ectopic expression of resistant c-ABL (T315I) mutant did not block the 
induction following imatinib exposure. It is likely that imatinib induces autophagy by 
inhibiting mTOR, the negative regulator of autophagy, and it was shown to potentially 
be associated with ER (endoplasmic reticulum) stress, but the exact molecular 
mechanism is still not clear and is being investigated in our laboratory. Importantly, 
our data were supported by in vivo experiments in a mouse model. As published by 
Altman et al, transplantation of Bcr-Abl expressing haemopoietic cells that were 
depleted of Atg3 by conditional deletion, to lethally irradiated mice revealed that Bcr-
Abl failed to induce leukaemia in an autophagy ablated background.87   
All the aforementioned promising results within the CML stem cell population have 
led to the initiation of the Phase II CHOICES (CHlOroquine and Imatinib 
Combination to Eliminate Stem cells) clinical trial. The CHOICES trial is a 
randomised trial of imatinib versus HCQ and imatinib for CML patients in major 
cytogenetic response (MCyR) with residual disease detectable by quantitative 
polymerase chain reaction (q-PCR) and is the first clinical trial using autophagy 
inhibition in CML. 
To support the role of active mTOR in blocking autophagy in BCR-ABL expressing 
cells, inhibition of mTOR using OSI-027, that inhibits both mTORC1 and mTORC2 
(the two separate mTOR complexes),  has recently been shown to induce autophagy 
in K562 cells.88 Furthermore, combination of OSI-027 with CQ resulted in increased 
apoptosis indicating that autophagy was acting as a survival mechanism following 
OSI-027 treatment. 
Paradoxically, drug treatment has also been shown to induce autophagic cell death 
(type II apoptosis) in imatinib sensitive and imatinib resistant K562 cells.89 Puissant et 
al showed that resveratrol (phytoalexin produced naturally by several plants) 
treatment induced apoptosis and autophagy through AMPK-dependent inhibition of 
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the mTOR pathway. Following autophagy inhibition with either bafilomycin A1 or 
knockdown of ATG5 or LC3, resveratrol-induced apoptosis was partially rescued. It 
was also shown that bafilomycin A1 reduced resveratrol-induced cell death in primary 
CD34+ CML cells, with the opposite effect seen on imatinib-induced death where 
bafilomycin A1 enhanced the imatinib effect (consistent with our previous results).49,89 
These results underline the importance of understanding the type of autophagy 
induction following specific types of stress and anticancer treatment so the most 
appropriate manipulation of autophagy can be applied for therapeutic intervention. 
On-going and future investigation regarding the use of autophagy regulators in vivo 
will shed light on this enigma since autophagy response differs not only among 
different patients and different organs within the same patient, but also among cells 
within the same tumour.69 Thus, how CHOICES and other clinical trials’ patients 
respond to combination therapy with an autophagy inhibitor, will give us essential 
information on whether modulation of autophagy in human tumours is a future 
therapeutic option of merit. 
  
Autophagy inhibition in the clinic 
 
None of the available autophagy inhibitors is specific for autophagy and hence, affect 
other pathways. Nevertheless, CQ and HCQ are used as anti-malarial drugs and have 
been approved for treatment of other diseases, e.g. rheumatoid arthritis. Since HCQ is 
less toxic than CQ to the retina, a number of clinical trials have now been initiated in 
patients with haemopoietic or solid tumours using HCQ as an autophagy inhibitor.90-91 
These trials use, like the CHOICES trial, the combination of HCQ with a targeted 
therapy, or in combination with cytotoxic chemotherapy or metabolic stress inducers, 
for example in multiple myeloma, where HCQ is used in combination with the 
proteasome inhibitor bortezomib (velcade).90 But the overall hypothesis in all these 
trials is that autophagy is a survival mechanism of therapeutic resistance and blocking 
autophagy might increase the effect of the anticancer treatment. Although CQ has 
convincingly been shown to block autophagy in vitro, it still remains to be shown that 
drug/radiation-induced autophagy can be blocked using 400-800 mg daily dosing of 
HCQ in human tumours in vivo. Therefore, developing rigorous biomarkers in order 
to monitor autophagy in vivo will be critical.  
 
Conclusion: In many ways CML represents a model disease and a paradigm for 
cancer stem cells, oncogene addiction and targeted therapies. With the introduction of 
TKI for the treatment of CML we have embarked on a journey aiming to cure the 
disease with orally administered, non-toxic agents. The major current impediment to 
cure for patients in CP resides in the cancer stem cell population that is neither 
oncogene addicted nor sensitive to TKI. The recent discovery that TKI induce the 
process of autophagy, which in turns protects CML stem cells, has presented the field 
with an exciting opportunity to kill one bird, CML, with two stones, TKI and 
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Figure 1: BCR-ABL signaling mimics growth factor activation 
Growth factors are known to activate receptor tyrosine kinases (RTKs) leading to 
activation of the RAS and PI3-K/AKT pathways. These pathways are commonly 
activated in human cancers. Phosphorylation of tyrosine 177 within the BCR part of 
BCR-ABL leads similarly to activation of these pathways by interacting with the SH2 
domain in GRB2. GRB2 activates RAS by interacting with SOS and it also activates 
PI3-K by mediating phosphorylation of GAB2. Constitutive activation of PI3-K leads 
to conversion of phosphatidylinositol bisphosphate (PIP2) to phosphatidylinositol 
triphosphate (PIP3). This can be inhibited by PTEN, a phosphatase that is 
downregulated in many cancers. PIP3 provides a platform for the recruitment of the 
serine/threonine kinases AKT and 3-phosphoinositide-dependent protein kinase-1 
(PDK1), leading to phosphorylation and activation of AKT. Activated AKT 
phosphorylates many downstream targets that affect proliferation and survival, 
including the FOXO transcription factors and the pro-apoptotic protein BAD. AKT 
mediated phosphorylation of FOXO inhibits its nuclear entry and therefore suppresses 
its activity, leading to increased cell proliferation. The pro-apoptotic activity of BAD 
is also suppressed following AKT mediated phosphorylation. Phosphorylation of 
BAD prevents it binding to and inhibiting the function of anti-apoptotic BCL-2 
proteins which inhibit the pro-apoptotic proteins BAK and BAX. AKT activation 
leads to downregulation of the tumour suppressor p53 by increasing the levels of the 
negative regulator of p53, MDM2. AKT also phosphorylates the serine/threonine 
kinase mTOR. Activated mTOR promotes protein translation and inhibits autophagy. 
BCR-ABL also leads to the activation of the JAK/STAT pathway, a pathway that is 
frequently activated in myeloproliferative diseases. JAK is a non-receptor tyrosine 
kinase and is normally activated by growth factors. BCR-ABL has been shown to 
induce IL-3 and G-CSF production that could lead to activation of this pathway. 
Active JAK phosphorylates the transcription factor STAT5 and BCR-ABL has also 





Figure 2: Molecular mechanism of autophagy 
Autophagy initiation starts with activation of the ULK1/2 kinase complex which also 
includes ATG13 and FIP200. mTOR suppresses the activity of this complex by 
phosphorylating ULK1 and ATG13 on “negative” sites. This complex then becomes 
active following AMPK activation and mTOR inhibition, for example during 
starvation or treatment with rapamycin. Phosphorylated and now active ULK1 
promotes phosphorylation of ATG13 and FIP200 and dissociates from mTOR. The 
PI3-K-III VPS34 is critical for further autophagosome formation. VPS34 forms a 
complex with VPS15, UVRAG, AMBRA1 and BECLIN1. This complex can be 
inhibited by the anti-apoptotic protein BCL-2 which can interact with BECLIN1 
through the BH3 domain in BECLIN1. Autophagosome completion is mediated by 
the ATG8 (LC3)-PE and ATG12/ATG5 conjugation systems. These systems perform 
the lipid modification of LC3-I leading to LC3-II-PE binding to the autophagosomal 
membrane (see text for more details). The conversion of LC3-I to LC3-II is 
commonly used to monitor autophagy by various assays. Completed autophagosomes 
contain materials such as proteins and organelles that can be digested following 
autophagosome fusion with lysosomes. Lysosomes have low pH and abundance of pH 
sensitive enzymes that can break down waste materials and cellular debris. The 
autolysosome degradation can therefore remove unwanted materials such as damaged 
proteins in addition to providing the cell with new building blocks for cellular 
maintenance. The mTOR inhibitor rapamycin can be used to promote autophagy 
induction. VPS34 inhibitors, such as 3-MA and Wortmannin can be used to inhibit 
early stages of autophagy. Bafilomycin A1, CQ, HCQ and NH4Cl, which inhibit the 































































































































MNC = Mononuclear cell. 
